RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx announced full enrollment completion in its Phase III TIGeR-PaC trial targeting locally advanced pancreatic cancer, a scheduled clinical milestone in the drug development pathway. This represents procedural progress within the expected trial timeline rather than an unexpected catalyst or change to the clinical program.

The trial completion is projected for H1 2027, with topline data readout expected in H2 2027. These timelines align with standard Phase III oncology trial progression and provide visibility on future data delivery, but do not constitute new efficacy or safety information that would alter near-term investment thesis.

Pancreatic cancer remains an area of significant unmet medical need, and successful late-stage data could become materially important upon release. However, the announcement itself is a routine operational update reflecting normal trial execution rather than a competitive shock or regulatory surprise.

Sector implication: Biotech pipeline announcements of this type typically exhibit low correlation with broad equity markets, as micronutrition-stage clinical progress is priced gradually into specialist healthcare investors. The 18-24 month lag until data readout limits immediate market impact.